Revenue Collapses 70% as Organogenesis Swings to $29.6M Quarterly Loss, Cuts Full-Year Outlook
ORGO is trading near its 52-week low of $0.73 (4.4% above the low).
Summary
Third-quarter net revenue fell to $45.5 million from $150.5 million a year ago, a 70% drop, with Advanced Wound Care down 73% to $38.2 million. The company swung to a $32.8 million net loss from $21.6 million of net income, a loss of 25 cents a share, and adjusted EBITDA went from $30.1 million positive to a $22.4 million loss. Full-year 2026 revenue guidance is now $179.4 million to $200.0 million, a 65%-68% decline, and management said the fourth-quarter sequential recovery will come at a more measured rate than previously assumed. Cash fell to $26.9 million from $94.3 million at December 31, 2025, with no debt outstanding — a thin cushion for a company burning cash, which is why the $75M at-the-market program launched in August matters. The stock sits near its 52-week low of $0.73, and this print confirms the CMS reimbursement reset is still crushing the core wound care business.
At the time of this announcement, ORGO was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.1M. The 52-week trading range was $0.73 to $7.08. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.